ADNI data link severe anxiety to cognitive decline in Alzheimer's disease

Researchers analyzing Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort data found that frequent anxiety and overall neuropsychiatric symptoms strongly correlate with lower global cognitive performance in individuals with Alzheimer's disease, according to a study published in Genomic psychiatry :. Anxiety disorders affect roughly 40% to 50% of people diagnosed with the condition doi.orgGenomic psychiatry :doi.orgOpen source ↗. The findings provide translational rationale for testing Cog-201, an investigational gene therapy targeting the 5-HT2A serotonin receptor designed to simultaneously alleviate anxiety and cognitive impairment.

Neuropsychiatric burden and amyloid accumulation

The team evaluated global cognition via the Mini-Mental State Examination (MMSE) alongside neuropsychiatric symptoms tracked using the Neuropsychiatric Inventory (NPI). Across the full cohort at the 12-month mark, higher total NPI scores significantly correlated with lower MMSE scores (r = −0.32). While participants experiencing weekly anxiety scored similarly to those with no anxiety, subjects with daily or continuous anxiety scored significantly lower on cognitive assessments. Higher overall neuropsychiatric burden also demonstrated a modest, statistically significant correlation with increased cortical amyloid PET burden, though amyloid levels alone did not fully explain the cognitive correlation.

Serotonergic background and clinical rationale

Investigators explored whether variants in serotonergic genes affect this dynamic. In subjects carrying the HTR2A rs6313 CT genotype, researchers noted an inverse correlation between MMSE performance and anxiety (r = −0.21). A steeper negative slope appeared in carriers of the SLC6A4 rs25531 CC genotype within 5-HTTLPR, although subgroup sample sizes were limited. The authors emphasized that these exploratory genetic observations require cautious interpretation and independent replication.

In preclinical rodent models, Cog-201 knocked down the 5-HT2A receptor using shRNA, which improved memory metrics and reduced anxiety-related behaviors doi.orgGenomic psychiatry :doi.orgOpen source ↗. No human patients received Cog-201 in this study, which served strictly to establish a clinical rationale. The authors reported that these ADNI findings justify future clinical trials of the gene therapy targeting both behavioral and cognitive symptoms in Alzheimer's disease.